Nanotechnology-based cancer therapeutics--promise and challenge--lessons learned through the NCI Alliance for Nanotechnology in Cancer.
The new generation of nanotechnology-based drug formulations is challenging the accepted ways of cancer treatment. Multi-functional nanomaterial constructs have the capability to be delivered directly to the tumor site and eradicate cancer cells selectively, while sparing healthy cells. Tailoring of the nano-construct design can result in enhanced drug efficacy at lower doses as compared to free drug treatment, wider therapeutic window, and lower side effects. Nanoparticle carriers can also address several drug delivery problems which could not be effectively solved in the past and include reduction of multi-drug resistance effects, delivery of siRNA, and penetration of the blood-brain-barrier. Although challenges in understanding toxicity, biodistribution, and paving an effective regulatory path must be met, nanoscale devices carry a formidable promise to change ways cancer is diagnosed and treated. This article summarizes current developments in nanotechnology-based drug delivery and discusses path forward in this field. The discussion is done in context of research and development occurring within the NCI Alliance for Nanotechnology in Cancer program.
Farrell
Dorothy
D
Center for Strategic Scientific Initiatives, Office of Director, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.
Ptak
Krzysztof
K
Panaro
Nicholas J
NJ
Grodzinski
Piotr
P
D000068196:Albumin-Bound Paclitaxel; D000418:Albumins / Q000494:pharmacology; D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods*; D018432:Drug Resistance, Multiple / Q000187:drug effects; D006801:Humans; D051379:Mice; D050997:Nanomedicine / Q000379:methods* / Q000639:trends; D053758:Nanoparticles; D054547:National Cancer Institute (U.S.); D009369:Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D017239:Paclitaxel / Q000494:pharmacology; D034741:RNA, Small Interfering / Q000627:therapeutic use; D014481:United States
D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D034741:RNA, Small Interfering; D017239:Paclitaxel
Nat Nanotechnol. 2007 Dec;2(12):751-60
18654426
Gynecol Oncol. 2000 Oct;79(1):116-9
11006042
Clin Cancer Res. 2008 May 15;14(10):3193-203
18483388
Adv Mater. 2008 May 5;20(9):1630-1635
21687830
Small. 2009 Mar;5(6):694-700
19263431
Annu Rev Med. 2008;59:251-65
17937588
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2586-91
18272481
J Clin Oncol. 2005 Nov 1;23(31):7768-71
16204007
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9343-8
18607000
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6944-9
16203786
Biomaterials. 2009 Feb;30(4):649-57
18990439
Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11394-9
19564622
Mol Pharm. 2009 May-Jun;6(3):659-68
19267452
J Am Chem Soc. 2008 Feb 20;130(7):2146-7
18225903
Adv Drug Deliv Rev. 2009 Nov 12;61(13):1189-92
19682514
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Cancer Res. 2009 Aug 1;69(15):6200-7
19638572
Expert Rev Mol Diagn. 2006 May;6(3):307-18
16706735
Clin Cancer Res. 2005 Jun 1;11(11):4136-43
15930349
Small. 2009 Feb;5(2):256-64
19089837
Clin Pharmacol Ther. 2008 May;83(5):761-9
17957183
ACS Nano. 2010 Feb 23;4(2):589-94
20175564
Clin Cancer Res. 2007 Apr 1;13(7):2207-15
17404105
Nat Rev Cancer. 2005 Mar;5(3):161-71
15738981
Clin Cancer Res. 2009 Jan 1;15(1):181-9
19118045
Cancer Res. 2007 May 15;67(10):4843-50
17510414
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010 Jan-Feb;2(1):99-112
20049834
Biomaterials. 2009 Mar;30(8):1627-34
19111339
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009 May-Jun;1(3):264-71
20049796
Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15549-54
17875985